Rethinking Cancer Innovation: How Scientist- and Physician-Led Biotech Is Shaping the Future of Precision Oncology

For those battling cancer, breakthroughs mean a possible new lease on life. Under Dr. Gabi Hanna's leadership, scientist-led Lamassu Biotech aims to revive the body's own tumor suppressor gene to bring hope and healing to patients battling rare cancers, and why he says speed is an ethical obligation.

Cancer research has advanced significantly over the past decade, yet translating discoveries into effective treatments remains one of healthcare's hardest problems. Precision oncology is opening new ways to target cancer at the molecular level, but patients with rare, aggressive, and hard-to-treat tumors still face limited options, and many are still treated with drugs developed more than 60 years ago. For Hanna, a physician-entrepreneur and co-founder of the clinical-stage biotechnology company, closing that gap requires more than scientific innovation. It requires a different approach to how traditional biotech companies are founded, developed, and connected to the wider medical community.

When several major pharmaceutical companies ended their research programs involving MDM2 inhibitors after struggling with toxicity and dose limitations, the patients who had been counting on the novel therapies were left with nothing. More than 2,000 oncologists, researchers, and patients signed a petition with The Life Raft Group asking for the mechanism to be developed. Dr. Gabi Hanna's company, Lamassu Biotech, is now stepping into the void to advance this promising research.

Hanna's approach reflects a growing movement toward entrepreneur-, scientist-, and physician-led biotechnology. Rather than building a company primarily around financial investment first and science second, this model puts scientific knowledge, clinical experience, and unmet patient needs at the center of business development. With experience across three drug companies, Hanna brings a firsthand understanding of what it takes to move a therapeutic concept from the laboratory toward the clinic. "Our job is to transfer scientific knowledge into tangible real products that help patients," he says.

He co-founded Lamassu with his brother, Dr. Rabi Hanna, Chairman of Pediatric Oncology at Cleveland Clinic, and Dr. Greg Palmer, PhD, a professor at Duke University and a friend of more than 20 years. From the outset, the founding team has combined entrepreneurial, clinical, and academic research experience. The company has since added former FDA Commissioner Dr. Stephen Hahn to its team and board, bringing deep regulatory experience as it moves a novel therapy through development. Its network includes relationships and partnerships with leading institutions such as Cleveland Clinic, Mayo Clinic, and MD Anderson Cancer Center.

The philosophy also speaks to a broader question facing the industry: How can companies ensure that promising discoveries receive the resources, institutional support, and commercial attention they need to reach patients?

Biotechnology is a demanding business. Traditionally, bringing a new drug to patients takes years, even decades, of research, substantial capital, sustained regulatory engagement, and collaboration with medical institutions. Many emerging companies depend heavily on venture capital to fund that work. Hanna's model places particular emphasis on involving scientists and physicians who understand both the biology being investigated and the clinical problems it is meant to solve. That distinction matters because drug development is not simply a financial exercise: decisions about research priorities, therapeutic mechanisms, and clinical direction require a detailed grasp of the science. A scientist-led structure keeps those decisions tied to the company's long-term strategy, and, Hanna argues, to the patients it is meant to serve.

For Hanna, entrepreneurship and research are complementary rather than separate disciplines. Relationships with experienced clinicians, research institutions, and regulatory experts give a company a stronger foundation for evaluating new therapeutic opportunities.

One of the most important shifts in modern oncology is the move toward precision medicine. Conventional treatments such as chemotherapy remain essential for many patients, but they also damage healthy cells, impose significant physical burdens, and work unevenly across cancer types and individual patients. Precision oncology instead examines the molecular and genetic features of individual tumors, using next-generation sequencing, gene-expression analysis, and advanced computational tools, to understand why some cancers respond to a given treatment while others do not.

A central target in this field is p53, a tumor-suppressor protein that regulates cell growth and triggers the elimination of damaged cells. In many cancers, the p53 pathway is impaired, but not always because the p53 gene itself is mutated. Often a regulatory protein called MDM2 binds to p53 and switches it off. Blocking that interaction could, in principle, restore the cell's own tumor-suppressing machinery.

This is the mechanism behind Lamassu's lead program, SA53, an MDM2-p53 inhibitor now in a Phase 1/2a clinical trial for patients with advanced solid tumors, including liposarcoma, a rare cancer in which MDM2 is frequently amplified. "Roughly half of all tumors still carry a working p53 gene," Hanna says. "MDM2 is simply holding it hostage. Release it, and the cell's own defenses can do the work. If or when a drug like SA53 is approved, as many as half of all cancer patients could potentially benefit from SA53 as monotherapy or combined therapy."

For Hanna, the broader opportunity is to advance treatments that go after the biological drivers of cancer rather than relying solely on conventional approaches alone. Lamassu's focus is rare oncology indications, where patients often have no good options and are still treated with drugs developed more than 60 years ago.

In October 2026, Lamassu presented its interim clinical safety and pharmacokinetic data from its first-in-human SA53 study at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The company reported escalating the dose to 16 times the starting level without clinically significant dose-limiting toxicities, a notable contrast with earlier MDM2 inhibitors from large pharmaceutical companies, several of which were abandoned after Grade 3–4 toxicities capped dose escalation at far lower levels.

The findings drew considerable interest from oncologists eager to see the treatment reach more patients who currently have poor options. Additional conference presentations have been accepted, the company has been awarded an NCI/NIH grant, and a further NIH application is under way. Hanna is careful to frame these milestones for what they are. Institutional relationships, conference presentations, grants, and physician endorsements are markers of scientific engagement, but not the final proof of clinical effectiveness. It requires collective work to solve a problem as big as cancer and to bring the newest precision oncology to every patient. "The only test that matters is whether the drug is safe and helps patients in a properly designed trial," he says. "Everything else is a step toward that."

For an emerging biotech, scientific credibility is only part of the challenge. Sustaining research requires capital, strategic partnerships, commercial relationships, and a clear-eyed understanding of the healthcare marketplace. This is why Hanna believes biotech companies must communicate beyond specialist audiences. Investors and business leaders need to understand not only the science but also the commercial and clinical problems a treatment aims to solve. Greater visibility connects companies with investors, institutional partners, and professional networks, while helping patients and clinicians learn about progress in areas where options remain scarce.

The case for supporting innovation is especially pressing in rare cancers. Small patient populations make research harder to finance, and clinical trials face recruitment and operational hurdles. Without sufficient investment and institutional interest, promising approaches risk losing out to treatments aimed at larger markets. A sustainable biotech model must therefore balance scientific ambition with financial discipline and a clear understanding of patient need.

Hanna also argues that speed deserves far more weight than it usually gets. In his view, accelerating development is an ethical question before it is a business one: those who hold the knowledge and resources to help patients carry a moral obligation to do so, and every day a treatment is delayed is a day on which more patients die. "Every day a treatment is delayed is a day on which more patients die," he says. "If you hold the knowledge and the resources to help, you have an obligation to move."

That obligation, he says, applies to founders, investors, and regulators alike. All three need to treat speed as a first-order consideration, especially for fatal diseases with no adequate treatment, where the cost of delay is measured in lives rather than quarters.

Lamassu's model is built around that principle. Its newest initiative, Lamassu IQ, applies AI tools to data from more than 10 years of research, preclinical studies, over 100 animal studies, ongoing clinical programs, genetic data, and other field knowledge to optimize dosing, patient selection, and trial design to accelerate development. The company also works in parallel with leading U.S. academic institutions and researchers, rather than following the conventional, sequential path that has defined drug development for decades.

According to the American Cancer Society's 2026 report, five-year relative survival across all cancers has reached 70% for people diagnosed between 2015 and 2021. That is meaningful progress, but outcomes remain far worse for patients with distant-stage disease. For patients with rare cancers and sarcomas in particular, the need for innovation is acute. Improving outcomes will require continued investment in research, broader access to genomic testing, and clinical trials that patients can reach beyond major research centers.

Hanna's perspective reflects a conviction that the future of oncology depends on closer collaboration among scientific expertise, medical institutions, and entrepreneurial leadership, creating an environment in which promising discoveries receive the attention, funding, and scrutiny they need to progress responsibly.

For Hanna, the measure of cancer innovation is not the number of discoveries announced or the visibility of a biotechnology company, but whether treatments withstand scientific scrutiny and change what happens to patients. "There are people waiting on this," he says. "Our job is to get it to them, and to get it right."

We've all heard about the Cancer Moonshot. Hanna looks to utilize his passion for people, science, and entrepreneurship to chart a course for the stars, transforming the way we treat millions of patients. As precision oncology matures, scientist-led companies have an opportunity to shape that progress by connecting scientific possibility with practical development and keeping the next generation of cancer research focused on the people who need better options most.

Physicians, patients, and investors interested in the SA53 trial can find enrollment information on ClinicalTrials.gov and through the company's website at lamassubiotech.com.